# PRAX catalysts: Praxis Precision Medicines, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/prax/catalysts

> Praxis Precision Medicines, Inc. (PRAX) has 14 upcoming catalysts. The next is the Praxis Precision Medicines, Inc. primary completion, December 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: half-year only, quarter only, year only, month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Praxis Precision Medicines, Inc. |
| Ticker | PRAX (Nasdaq) |
| SEC CIK | 1689548 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/prax |

## Cash runway

Cash $1.29B as of 2026-09-30; quarterly burn $81.7M; about 47.2 months of runway at that rate (XBRL company facts, accession 0001689548-26-000089).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| 1H 2025 | [Praxis Precision Medicines, Inc. topline data readout](https://sec-api.dev/companies/prax/catalysts) | PRAX |  | scheduled | "The RADIANT Phase 2 study for FOS and generalized epilepsy is currently enrolling patients, with topline results expected in the first half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954825000021/a8-kexhibit991.htm)) |
| Q1 2025 | [Praxis Precision Medicines, Inc. interim data readout](https://sec-api.dev/companies/prax/catalysts) | PRAX |  | scheduled | "Study 1 of Essential3 program for ulixacaltamide in essential tremor (ET) on track for Q1 2025 interim analysis; NDA filing for ulixacaltamide expected in 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954825000021/a8-kexhibit991.htm)) |
| 2025 | [Relutrigine topline data readout](https://sec-api.dev/pdufa/relutrigine) | PRAX |  | scheduled | "As previously disclosed, Praxis Precision Medicines, Inc. (the "Company") anticipates reporting topline results from the RADIANT Phase 2 study by mid-year 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1689548/000168954825000086/prax-20250717.htm)) |
| 1H 2025 | [Elsunersen trial start](https://sec-api.dev/pdufa/elsunersen) | PRAX |  | scheduled | "With regulatory feedback on the elsunersen program, we expect to initiate the pivotal trial in the first half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954825000021/a8-kexhibit991.htm)) |
| mid-2025 | [Relutrigine trial start](https://sec-api.dev/pdufa/relutrigine) | PRAX |  | scheduled | "oPraxis has completed discussions with the FDA on a trial for broad DEEs and will initiate the EMERALD registrational study in mid-2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954825000056/praxisq12025pr.htm)) |
| May 2025 | [Relutrigine topline data readout](https://sec-api.dev/pdufa/relutrigine) | PRAX |  | completed, positive | "For our relutrigine program (formerly known as PRAX-562), we announced positive topline results from the first cohort of our EMBOLD study in the third quarter of 2024, and disclosed updated data from the study's open-label extension through 11 months in May 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1689548/000168954825000111/prax-20250930.htm)) |
| May 2, 2025 | [Praxis Precision Medicines, Inc. earnings report](https://sec-api.dev/companies/prax/catalysts) | PRAX |  | completed | "Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954825000056/praxisq12025pr.htm)) |
| 2H 2025 | [Vormatrigine topline data readout](https://sec-api.dev/pdufa/vormatrigine) | PRAX | treatment resistant FOS | scheduled | "oPraxis has also initiated the POWER1 Phase 2/3 registrational study of vormatrigine for treatment resistant FOS, with topline results anticipated in the second half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954825000037/praxisye2024pr.htm)) |
| 2H 2025 | [Praxis Precision Medicines, Inc. topline data readout](https://sec-api.dev/companies/prax/catalysts) | PRAX |  | scheduled | "•The POWER1 Phase 2/3 registrational study for treatment resistant FOS is enrolling, with topline results expected in the second half of 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954825000056/praxisq12025pr.htm)) |
| Q3 2025 | [Elsunersen interim data readout](https://sec-api.dev/pdufa/elsunersen) | PRAX |  | scheduled | "While the interim analysis of Essential3 study 1 for ulixacaltamide was not what we expected, we are on track to complete both study 1 and study 2 for topline readout in the third quarter of this year." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954825000056/praxisq12025pr.htm)) |
| Q3 2025 | [Praxis Precision Medicines, Inc. topline data readout](https://sec-api.dev/companies/prax/catalysts) | PRAX |  | scheduled | "Given the advanced state of enrollment for both Study 1 and Study 2 in the Essential3 program, and in the context of the advice received by the IDMC, Praxis has decided to continue both studies to completion, with topline results expected in the third quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954825000037/praxisye2024pr.htm)) |
| July 2025 | [Praxis Precision Medicines, Inc. primary completion](https://sec-api.dev/companies/prax/catalysts) | PRAX | Focal Onset Seizure; Primary Generalized Epilepsy | delayed | "NCT06908356 (An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2025-07 (ESTIMATED); Lead Sponsor Praxis Precision Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06908356)) |
| Aug 2025 | [Vormatrigine topline data readout](https://sec-api.dev/pdufa/vormatrigine) | PRAX | focal onset seizures or generalized epilepsy | completed, positive | "In August 2025, we announced positive topline results from the first cohort of our first efficacy study, RADIANT, an open label study in patients with focal onset seizures or generalized epilepsy." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1689548/000168954825000111/prax-20250930.htm)) |
| August 4, 2025 | [Praxis Precision Medicines, Inc. earnings report](https://sec-api.dev/companies/prax/catalysts) | PRAX |  | completed | "Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954825000094/praxisq22025pr.htm)) |
| Q4 2025 | [Relutrigine interim data readout](https://sec-api.dev/pdufa/relutrigine) | PRAX |  | scheduled | "The interim analysis is planned to be conducted in the fourth quarter of 2025.Relutrigine is also being investigated in patients across all DEEs in the EMERALD trial." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954825000110/praxisq32025pr.htm)) |
| Oct 2025 | [Cerebrum (cerebrum) topline data readout](https://sec-api.dev/pdufa/cerebrum) | PRAX |  | completed, positive | "For our ulixacaltamide program within the Cerebrum™ platform, we announced positive topline results for the two studies in the Phase 3 Essential3 program in essential tremor, or ET, in October 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000047/prax-20260331.htm)) |
| October 10, 2025 | [Praxis Precision Medicines, Inc. primary completion](https://sec-api.dev/companies/prax/catalysts) | PRAX | Essential Tremor | completed | "NCT06087276 (Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2025-10-10 (ACTUAL); Lead Sponsor Praxis Precision Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06087276)) |
| October 16, 2025 | [Praxis Precision Medicines, Inc. topline data readout](https://sec-api.dev/companies/prax/catalysts) | PRAX |  | completed, positive | "On October 16, 2025, the Company announced positive topline results for the Phase 3 Essential3 program of ulixacaltamide in essential tremor ("ET")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1689548/000168954825000100/prax-20251016.htm)) |
| November 5, 2025 | [Praxis Precision Medicines, Inc. earnings report](https://sec-api.dev/companies/prax/catalysts) | PRAX |  | completed | "Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954825000110/praxisq32025pr.htm)) |
| November 12, 2025 | [PRAX-562 primary completion](https://sec-api.dev/pdufa/prax-562) | PRAX | SCN2A Encephalopathy; SCN8A Encephalopathy | completed | "NCT05818553 (A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2025-11-12 (ACTUAL); Lead Sponsor Praxis Precision Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05818553)) |
| Dec 2025 | [Praxis Precision Medicines, Inc. NDA/BLA submission](https://sec-api.dev/companies/prax/catalysts) | PRAX |  | completed | "•Following a positive pre-NDA meeting with the FDA in December 2025, Praxis has submitted an NDA for the treatment of ET." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000028/praxisye2025pr.htm)) |
| 1H 2026 | [Elsunersen topline data readout](https://sec-api.dev/pdufa/elsunersen) | PRAX |  | scheduled | "oThe second cohort of the EMBRAVE study evaluating safety and efficacy of elsunersen versus sham procedure continues enrolling patients in Brazil, with topline readout anticipated in the first half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954825000037/praxisye2024pr.htm)) |
| early 2026 | [Relutrigine NDA/BLA submission](https://sec-api.dev/pdufa/relutrigine) | PRAX |  | scheduled | "On December 11, 2025, the Company announced the completion of the planned discussion with the FDA, leading to the confirmation to file a New Drug Application for relutrigine in SCN2A and SCN8A DEEs in early 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1689548/000168954825000116/prax-20251209.htm)) |
| 1H 2026 | [Relutrigine topline data readout](https://sec-api.dev/pdufa/relutrigine) | PRAX |  | scheduled | "Relutrigine has Rare Pediatric Disease Designation in three indications: SCN1A epilepsy (Dravet syndrome), SCN2A and SCN8A DEEs oThe EMBOLD registrational cohort 2 continues to enroll strongly, with topline results expected no later than the first half of 2026, followed by potential NDA filing." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954825000056/praxisq12025pr.htm)) |
| 1H 2026 | [Praxis Precision Medicines, Inc. topline data readout](https://sec-api.dev/companies/prax/catalysts) | PRAX |  | scheduled | "•The POWER1 Phase 2/3 registrational study for FOS has completed recruitment, with topline readout expected in the first half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954825000110/praxisq32025pr.htm)) |
| 1H 2026 | [Praxis Precision Medicines, Inc. topline data readout](https://sec-api.dev/companies/prax/catalysts) | PRAX |  | scheduled | "oThe EMBOLD registrational cohort 2 in SCN2A and SCN8A DEEs continues to enroll well, with topline results expected no later than the first half of 2026, followed by a potential NDA submission." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954825000094/praxisq22025pr.htm)) |
| 1H 2026 | [Praxis Precision Medicines, Inc. topline data readout](https://sec-api.dev/companies/prax/catalysts) | PRAX |  | scheduled | "Topline results expected 1H 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954825000103/praxiscorporatedeckoctob.htm)) |
| 1H 2026 | [Vormatrigine NDA/BLA submission](https://sec-api.dev/pdufa/vormatrigine) | PRAX |  | scheduled | ""The other two programs in the clinic, vormatrigine and elsunersen, will both have topline results in the first half of 2026, keeping us on track for additional NDA submissions in the next two years." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000028/praxisye2025pr.htm)) |
| February 19, 2026 | [Praxis Precision Medicines, Inc. earnings report](https://sec-api.dev/companies/prax/catalysts) | PRAX |  | completed | "Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000028/praxisye2025pr.htm)) |
| Apr 2026 | [Elsunersen topline data readout](https://sec-api.dev/pdufa/elsunersen) | PRAX |  | completed, positive | "For our most advanced product candidate under the Solidus™ platform, elsunersen, we announced positive topline results in April 2026 from the EMBRAVE Part A study evaluating the safety and efficacy of elsunersen versus sham procedure for treating SCN2A gain-of-function DEE." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000089/prax-20260930.htm)) |
| Q2 2026 | [Praxis Precision Medicines, Inc. topline data readout](https://sec-api.dev/companies/prax/catalysts) | PRAX |  | scheduled | "•The POWER1 Phase 3 study for FOS completed enrollment and exceeded its original target; topline results are expected in the second quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000028/praxisye2025pr.htm)) |
| Q2 2026 | [Vormatrigine topline data readout](https://sec-api.dev/pdufa/vormatrigine) | PRAX |  | scheduled | "•The POWER1 Phase 3 study for FOS is on track for topline results in the second quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000049/praxisq12026pr.htm)) |
| April 14, 2026 | [Praxis Precision Medicines, Inc. NDA/BLA acceptance](https://sec-api.dev/companies/prax/catalysts) | PRAX | essential tremor in adults | completed | "On April 14, 2026, Praxis Precision Medicines, Inc. announced that the U.S. Food and Drug Administration (the "FDA") has accepted for review its New Drug Application for ulixacaltamide HCl for the treatment of essential tremor in adults." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000033/prax-20260414.htm)) |
| May 7, 2026 | [Praxis Precision Medicines, Inc. earnings report](https://sec-api.dev/companies/prax/catalysts) | PRAX |  | completed | "Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000049/praxisq12026pr.htm)) |
| May 14, 2026 | [Praxis Precision Medicines, Inc. primary completion](https://sec-api.dev/companies/prax/catalysts) | PRAX | Focal Seizure | completed | "NCT06999902 (Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2026-05-14 (ACTUAL); Lead Sponsor Praxis Precision Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06999902)) |
| August 6, 2026 | [Praxis Precision Medicines, Inc. earnings report](https://sec-api.dev/companies/prax/catalysts) | PRAX |  | completed | "Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000082/praxisq22026pr.htm)) |
| September 27, 2026 | [Relutrigine PDUFA date](https://sec-api.dev/pdufa/relutrigine) | PRAX | SCN2A and SCN8A developmental and epileptic encephalopathies, or DEEs | scheduled | "FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) with a PDUFA target action date of September 27, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000049/praxisq12026pr.htm)) |
| Q4 2026 | [Relutrigine topline data readout](https://sec-api.dev/pdufa/relutrigine) | PRAX | broad DEEs | scheduled | "Topline results from the EMERALD study of relutrigine in broad developmental and epileptic encephalopathies (DEEs) expected in the fourth quarter of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000086/praxisq32026pr.htm)) |
| November 9, 2026 | [Praxis Precision Medicines, Inc. earnings report](https://sec-api.dev/companies/prax/catalysts) | PRAX |  | completed | "Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000086/praxisq32026pr.htm)) |
| December 2026 | [Praxis Precision Medicines, Inc. primary completion](https://sec-api.dev/companies/prax/catalysts) | PRAX | Developmental and Epileptic Encephalopathy 1 | scheduled | "NCT07010471 (A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Praxis Precision Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07010471)) |
| Dec 2026 to Mar 2027 | [Praxis Precision Medicines, Inc. topline data readout](https://sec-api.dev/companies/prax/catalysts) | PRAX | Developmental and Epileptic Encephalopathy 1 | scheduled | "NCT07010471 (A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Praxis Precision Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07010471)) |
| December 2026 | [Praxis Precision Medicines, Inc. primary completion](https://sec-api.dev/companies/prax/catalysts) | PRAX | Epileptic Encephalopathy; SCN2A Encephalopathy | scheduled | "NCT07019922 (A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Praxis Precision Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07019922)) |
| Dec 2026 to Mar 2027 | [Praxis Precision Medicines, Inc. topline data readout](https://sec-api.dev/companies/prax/catalysts) | PRAX | Epileptic Encephalopathy; SCN2A Encephalopathy | scheduled | "NCT07019922 (A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Praxis Precision Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07019922)) |
| December 27, 2026 | [Relutrigine PDUFA date](https://sec-api.dev/pdufa/relutrigine) | PRAX | SCN2A and SCN8A developmental and epileptic encephalopathies | scheduled | "56 D E V E L O P M E N T A L & E P I L E P T I C E N C E P H A L O P A T H I E S Relutrigine First medicine designed for SCN2A and SCN8A DEEs Dec 27, 2026 PDUFA date" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000091/praxis_investorxdayx2026.htm)) |
| 2027 | [Vormatrigine topline data readout](https://sec-api.dev/pdufa/vormatrigine) | PRAX |  | scheduled | "POWER2 is enrolling patients, with completion expected in the second half of 2026 and topline results expected in 2027." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000029/prax-20251231.htm)) |
| 2027 | [Elsunersen topline data readout](https://sec-api.dev/pdufa/elsunersen) | PRAX |  | scheduled | "We have initiated EMBRAVE3, a Phase 3 registrational study evaluating the efficacy, safety, tolerability and PK of elsunersen in early-onset SCN2A-DEE, and expect to announce topline results in 2027." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000029/prax-20251231.htm)) |
| 2027 | [PRAX-215 topline data readout](https://sec-api.dev/pdufa/prax-215) | PRAX |  | scheduled | "•PRAX-215 is a pan-sodium channel molecule currently being evaluated in a Phase 1 SAD/MAD study with a readout expected in 2027 and is being carried forward into chronic and acute pain trials." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000091/prax-20261112.htm)) |
| 2027 | [Praxis Precision Medicines, Inc. topline data readout](https://sec-api.dev/companies/prax/catalysts) | PRAX |  | scheduled | "Topline results are anticipated in 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000086/praxisq32026pr.htm)) |
| January 2027 | [Praxis Precision Medicines, Inc. primary completion](https://sec-api.dev/companies/prax/catalysts) | PRAX | Focal Epilepsy | scheduled | "NCT07505004 (Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor Praxis Precision Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07505004)) |
| Jan to Apr 2027 | [Praxis Precision Medicines, Inc. topline data readout](https://sec-api.dev/companies/prax/catalysts) | PRAX | Focal Epilepsy | scheduled | "NCT07505004 (Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor Praxis Precision Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07505004)) |
| January 29, 2027 | [Cerebrum (cerebrum) PDUFA date](https://sec-api.dev/pdufa/cerebrum) | PRAX | essential tremor, or ET | scheduled | "For our ulixacaltamide program within the Cerebrum™ platform, we submitted a New Drug Application, or NDA, for ulixacaltamide HCl for the treatment of essential tremor, or ET, to the FDA based on the positive results of our two studies in the Phase 3 Essential3 program in ET, and it was accepted for review with a target action date under the Prescription Drug User Fee Act, or PDUFA, of January 29, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000089/prax-20260930.htm)) |
| May to Aug 2028 | [Vormatrogine topline data readout](https://sec-api.dev/pdufa/vormatrogine) | PRAX | Epilepsy, Tonic-Clonic; Focal Seizure; Primary Generalized Seizure | scheduled | "NCT07287163 (Clinical Trial of Vormatrigine in Adult Patients With Epilepsy): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-05-31 (ESTIMATED); Lead Sponsor Praxis Precision Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07287163)) |
| May 2028 | [Vormatrogine primary completion](https://sec-api.dev/pdufa/vormatrogine) | PRAX | Epilepsy, Tonic-Clonic; Focal Seizure; Primary Generalized Seizure | scheduled | "NCT07287163 (Clinical Trial of Vormatrigine in Adult Patients With Epilepsy): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-05-31 (ESTIMATED); Lead Sponsor Praxis Precision Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07287163)) |

## Drugs

- [Cerebrum (cerebrum)](https://sec-api.dev/pdufa/cerebrum): essential tremor, or et
- [Elsunersen](https://sec-api.dev/pdufa/elsunersen): 
- [PRAX-215](https://sec-api.dev/pdufa/prax-215): 
- [PRAX-562](https://sec-api.dev/pdufa/prax-562): SCN2A Encephalopathy
- [Relutrigine](https://sec-api.dev/pdufa/relutrigine): broad dees, scn2a and scn8a developmental and epileptic encephalopathies, or dees, scn2a and scn8a dees remains, scn2a and scn8a developmental and epileptic encephalopathies, scn2a-dee and scn8a-dee
- [Vormatrigine](https://sec-api.dev/pdufa/vormatrigine): focal onset seizures or generalized epilepsy, treatment resistant fos
- [Vormatrogine](https://sec-api.dev/pdufa/vormatrogine): Epilepsy, Tonic-Clonic

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/prax/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PRAX catalysts: Praxis Precision Medicines, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/prax/catalysts

```bibtex
@misc{secapidev_companies_prax_catalysts_20261116,
  title        = {PRAX catalysts: Praxis Precision Medicines, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/prax/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_prax_catalysts_20261116","title":"PRAX catalysts: Praxis Precision Medicines, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/prax/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
